| Code | CSB-RA005271MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to lampalizumab, targeting complement factor D (CFD), a highly specific serine protease that plays a critical role in the alternative complement pathway. CFD, also known as adipsin, cleaves factor B when bound to C3b, generating the C3 convertase complex that amplifies complement activation. This protein is constitutively active in plasma and represents the rate-limiting enzyme of the alternative pathway, making it a strategic target for complement-mediated inflammatory conditions. CFD dysregulation has been implicated in age-related macular degeneration (AMD), particularly geographic atrophy, as well as other complement-associated pathological processes including certain kidney diseases and inflammatory disorders.
Lampalizumab was developed as a therapeutic Fab fragment specifically designed to inhibit CFD activity and reduce complement-mediated tissue damage in dry AMD. This biosimilar antibody provides researchers with a valuable tool for investigating complement pathway mechanisms, exploring CFD's role in retinal degeneration and inflammatory disease models, and conducting preclinical studies related to complement inhibition strategies. It supports investigations into complement biology and potential therapeutic interventions targeting the alternative pathway.
There are currently no reviews for this product.